Mylan cuts forecasts on delays in new drugs, weak prices

(Reuters) - Mylan NV said on Wednesday that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability this year and in 2018, sending its shares down more than 6 percent.